康龙化成 PHARMARON

GENE THERAPY

GMP AAV Manufacturing

Pharmaron's Gene Therapy CDMO, located in Liverpool, UK, leverages its industry-leading expertise in process R&D, cGMP manufacturing and advanced analytical capabilities to support our partners in the development and manufacturing of gene therapies. Our world-class, cGMP manufacturing facility is purpose-designed for viral vector manufacture. Our experience coupled with state-of-the-art analytical and manufacturing technologies ensures we design, develop and deliver high quality, approvable gene therapies.

Capabilities

- Scalable suspension culture systems
- Range of GMP bioreactor scales (50L to 500L)
- Single-use technologies
- Chromatography-based purification
- Purification by ultra-centrifugation available
- Comprehensive analytical toolkit
- Unique viral vector characterisation analytics
- Dedicated QC analytical capabilities

Services

- **Targeted process development** using best-in-class analytics to drive scale-up to cGMP
  - Single-use technology
  - Suspension-based cell culture
  - Serotype dependent toolbox approach to downstream processing
  - Chromatography-based purification solutions
  - Automated and high-throughput development platforms
- **Starting material production,** management and release
- **Phase-appropriate** method validation and method transfer
- Advanced analytical toolkit for **process & product characterisation**
- **Rapid transition from development to clinical manufacture**, utilising Pharmaron's established platform processes and **multi-skilled process sciences team**
- Effective scale-up and technical transfer to one of our **GMP viral vector suites**
- **Quality assurance** and **qualified person** batch release
- **On-site cryo storage**

康龙化成 PHARMARON
www.pharmaron.com
bd@pharmaron.com

Laboratory Services

Chemistry, Manufacturing and Control

Clinical Development

Biologics & CGT

Pharmaron is a leading, fully integrated R&D service provider that supports the life science industry with diverse and well-established drug R&D service capabilities, from early discovery to clinical development.